ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 106 filers reported holding ASCENDIS PHARMA A/S in Q4 2018. The put-call ratio across all filers is 0.16 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $7,381 | -99.9% | 82,699 | +50.1% | 0.01% | +57.1% |
| Q2 2020 | $8,147,000 | +41.6% | 55,082 | +7.8% | 0.01% | +16.7% |
| Q1 2020 | $5,752,000 | +38.5% | 51,078 | +71.2% | 0.01% | +100.0% |
| Q4 2019 | $4,152,000 | -42.2% | 29,843 | -60.0% | 0.00% | -50.0% |
| Q3 2019 | $7,185,000 | -65.3% | 74,599 | -58.5% | 0.01% | -66.7% |
| Q2 2019 | $20,704,000 | +98.1% | 179,799 | +102.5% | 0.02% | +80.0% |
| Q1 2019 | $10,452,000 | +252.0% | 88,799 | +111.9% | 0.01% | +233.3% |
| Q3 2018 | $2,969,000 | -29.2% | 41,900 | -33.6% | 0.00% | +50.0% |
| Q2 2018 | $4,192,000 | +865.9% | 63,140 | +850.9% | 0.00% | – |
| Q1 2018 | $434,000 | -30.1% | 6,640 | -57.2% | 0.00% | -100.0% |
| Q4 2017 | $621,000 | -48.8% | 15,500 | -53.7% | 0.00% | 0.0% |
| Q3 2017 | $1,214,000 | +71.7% | 33,500 | +31.5% | 0.00% | 0.0% |
| Q2 2017 | $707,000 | – | 25,470 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,865,338 | $978,221,000 | 13.68% |
| Vivo Capital, LLC | 1,797,745 | $299,828,000 | 13.38% |
| Sofinnova Investments, Inc. | 1,109,874 | $185,105,000 | 11.02% |
| Avoro Capital Advisors LLC | 1,800,000 | $300,204,000 | 5.17% |
| Eventide Asset Management | 1,704,148 | $284,218,000 | 4.36% |
| Stenahm Asset Managment Ltd | 29,000 | $4,837,000 | 4.07% |
| Ghost Tree Capital, LLC | 105,000 | $17,512,000 | 3.90% |
| Eversept Partners, LP | 187,043 | $31,195,032 | 3.66% |
| Spyglass Capital Management LLC | 701,594 | $117,012,000 | 3.59% |
| Q Global Advisors, LLC | 23,183 | $3,866,000 | 2.72% |